Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer
- 504 Downloads
To update current recommendations on prevention, screening, diagnosis, and evaluation of bladder cancer (BC) based on a thorough assessment of the most recent literature on these topics.
A non-systematic review was performed, including articles until June 2017. A variety of original articles, reviews, and editorials were selected according to their epidemiologic, demographic, and clinical relevance. Assessment of the level of evidence and grade of recommendations was performed according to the International Consultation on Urological Diseases grading system.
BC is the ninth most common cancer worldwide with 430,000 new cases in 2012. Currently, approximately 165,000 people die from the disease annually. Absolute incidence and prevalence of BC are expected to rise significantly during the next decades because of population ageing. Tobacco smoking is still the main risk factor, accounting for about 50% of cases. Smoking cessation is, therefore, the most relevant recommendation in terms of prevention, as the risk of developing BC drops almost 40% within 5 years of cessation. BC screening is not recommended for the general population. BC diagnosis remains mainly based on cystoscopy, but development of new endoscopic and imaging technologies may rapidly change the diagnosis algorithm. The same applies for local, regional, and distant staging modalities.
A thorough understanding of epidemiology, risk factors, early detection strategies, diagnosis, and evaluation is essential for correct, evidence-based management of BC patients. Recent developments in endoscopic techniques and imaging raise the hope for providing better risk-adopted approaches and thereby improving clinical outcomes.
KeywordsNeoplasm, urinary bladder Risk factor Primary prevention Early detection of cancer Cystoscopy Neoplasm staging
MIF: data collection, data analysis, manuscript writing, and editing. LAK: data collection, data analysis, manuscript writing, and editing. MSC: data collection, data analysis, manuscript writing, and editing. AV: data collection, data analysis, manuscript writing, and editing. HBG: data collection, data analysis, manuscript writing, and editing. MK: data collection, data analysis, manuscript writing, and editing. PEC: data collection, data analysis, manuscript writing, and editing. BM: data collection, data analysis, manuscript writing, and editing. RS-S: data collection, data analysis, manuscript writing, and editing. MSS: data collection, data analysis, manuscript writing, and editing. RS-S: data collection, data analysis, manuscript writing, and editing. RV: data collection, data analysis, manuscript writing, and editing. MB: project development, data collection, data analysis, manuscript writing, and editing. AMK: project development, data collection, data analysis, manuscript writing, and editing.
Compliance with ethical standards
Conflict of interest
MCookson has received personal fees from Jansenn Biotech, MDxHealth, Astellas Pharma, Bayer, Genomic Health, Carden Jennings, Abbott, and Altor. HB Grossman has received personal fees from Abbott Molecular, Cepheid, and Nucleix. A Kamat is a consultant to the following companies; TMC Innovation, Merck, BMS, Arquer, MDxHealth, Photocure, Theralase, Cepheid, Medac, Asieris, Pfizer, and Astra Zeneca and has received research funding from FKD, Merck, Telesta, and Adolor. In addition, A Kamat has a patent CyPRIT—Cytokine Panel for Response to Intravesical Immunotherapy pending. The rest of the authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was not required, since this article does not contain any studies with human participants.
- 1.GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 (2013) International agency for research on cancer. http://globocan.iarc.fr. Accessed 24 Sept 2017
- 4.Human Development Reports. (2016) United Nations development programme. http://hdr.undp.org/sites/default/files/2016_human_development_report.pdf. Accessed 30 Apr 2018
- 5.Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Roupret M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, Lotan Y, Bachmann A, Zerbib M, Fisch M, Scherr DS, Vickers A, Shariat SF (2014) Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol 66(5):913–919. https://doi.org/10.1016/j.eururo.2013.11.040 Google Scholar
- 6.Thorstenson A, Hagberg O, Ljungberg B, Liedberg F, Jancke G, Holmang S, Malmstrom PU, Hosseini A, Jahnson S (2016) Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish national registry of urinary bladder cancer. Scand J Urol 50(4):292–297. https://doi.org/10.3109/21681805.2016.1158207 Google Scholar
- 7.Puente D, Malats N, Cecchini L, Tardon A, Garcia-Closas R, Serra C, Carrato A, Sala M, Boixeda R, Dosemeci M, Real FX, Kogevinas M (2003) Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol 43(1):53–62Google Scholar
- 8.Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth LA, Chun FK, Shariat SF, Fisch M, Rink M (2015) Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Euro J Surg Oncol 41(3):368–377. https://doi.org/10.1016/j.ejso.2014.03.003 Google Scholar
- 9.Sjostrom C, Thorstenson A, Strock V, Hosseini-Aliabad A, Aljabery F, Liedberg F, Sherif A, Malmstrom PU, Rosell J, Gardmark T, Jahnson S (2018) Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. Scand J Urol. https://doi.org/10.1080/21681805.2018.1462254 Google Scholar
- 11.Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA, Grotenhuis AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Besenbacher S, Gudbjartsson D, Stacey SN, Gudmundsson J, Johannsdottir H, Bjarnason H, Zanon C, Helgadottir H, Jonasson JG, Tryggvadottir L, Jonsson E, Geirsson G, Nikulasson S, Petursdottir V, Bishop DT, Chung-Sak S, Choudhury A, Elliott F, Barrett JH, Knowles MA, de Verdier PJ, Ryk C, Lindblom A, Rudnai P, Gurzau E, Koppova K, Vineis P, Polidoro S, Guarrera S, Sacerdote C, Panadero A, Sanz-Velez JI, Sanchez M, Valdivia G, Garcia-Prats MD, Hengstler JG, Selinski S, Gerullis H, Ovsiannikov D, Khezri A, Aminsharifi A, Malekzadeh M, van den Berg LH, Ophoff RA, Veldink JH, Zeegers MP, Kellen E, Fostinelli J, Andreoli D, Arici C, Porru S, Buntinx F, Ghaderi A, Golka K, Mayordomo JI, Matullo G, Kumar R, Steineck G, Kiltie AE, Kong A, Thorsteinsdottir U, Stefansson K, Kiemeney LA (2011) European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 20(21):4268–4281. https://doi.org/10.1093/hmg/ddr303 Google Scholar
- 18.Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M (1994) Cancer incidence in atomic bomb survivors. Part IV: comparison of cancer incidence and mortality. Radiat Res 137(2 Suppl):S98–S112Google Scholar
- 23.Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, Lopez-Abente G, Tzonou A, Chang-Claude J, Bolm-Audorff U, Jockel KH, Donato F, Serra C, Wahrendorf J, Hours M, T’Mannetje A, Kogevinas M, Boffetta P (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86(2):289–294Google Scholar
- 30.Buchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, Tjonneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Kaaks R, Chang-Claude J, Boeing H, Weikert S, Trichopoulou A, Naska A, Benetou V, Palli D, Sieri S, Vineis P, Tumino R, Panico S, van Duijnhoven FJ, Peeters PH, van Gils CH, Lund E, Gram IT, Sanchez MJ, Jakszyn P, Larranaga N, Ardanaz E, Navarro C, Rodriguez L, Manjer J, Ehrnstrom R, Hallmans G, Ljungberg B, Key TJ, Allen NE, Khaw KT, Wareham N, Slimani N, Jenab M, Boffetta P, Kiemeney LA, Riboli E (2011) Variety in vegetable and fruit consumption and risk of bladder cancer in the European prospective investigation into cancer and nutrition. Int J Cancer 128(12):2971–2979. https://doi.org/10.1002/ijc.25636 Google Scholar
- 31.Jakszyn P, Gonzalez CA, Lujan-Barroso L, Ros MM, Bueno-de-Mesquita HB, Roswall N, Tjonneland AM, Buchner FL, Egevad L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud MS, Chang-Claude J, Allen NE, Kiemeney LA, Key TJ, Kaaks R, Boeing H, Weikert S, Trichopoulou A, Oikonomou E, Zylis D, Palli D, Berrino F, Vineis P, Tumino R, Mattiello A, Peeters PH, Parr CL, Gram IT, Skeie G, Sanchez MJ, Larranaga N, Ardanaz E, Navarro C, Rodriguez L, Ulmert D, Ehrnstrom R, Hallmans G, Ljungberg B, Roddam AW, Bingham SA, Khaw KT, Slimani N, Boffetta PA, Jenab M, Mouw T, Michaud DS, Riboli E (2011) Red meat, dietary nitrosamines, and heme iron and risk of bladder cancer in the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiol biomark Prev 20(3):555–559. https://doi.org/10.1158/1055-9965.Epi-10-0971 Google Scholar
- 32.Continuous Update Project Report: Diet, Nutrition, Physical Activity and Bladder Cancer (2015) World cancer research fund international/american institute for cancer research. http://wcrf.org/bladder-cancer-2015. Accessed 30 Apr 2018
- 34.Bangma CH, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, Van Der Keur KA, Tjin S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ (2013) Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol 64(1):41–47. https://doi.org/10.1016/j.eururo.2013.02.036 Google Scholar
- 35.Moyer VA (2011) Screening for bladder cancer: US preventive services task force recommendation statement. Ann Intern Med 155(4):246–251. https://doi.org/10.7326/0003-4819-155-4-201108160-00008 Google Scholar
- 37.Hemstreet GP 3rd, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, Zang M, Zheng Q, Bane B, Asal N, Li G, Feng P, Hurst RE, Wang W (2001) Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 93(6):427–436Google Scholar
- 38.Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhausser H, Stenzl A, Bruning T (2011) The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int 108(4):546–552. https://doi.org/10.1111/j.1464-410X.2010.09971.x Google Scholar
- 43.Nakai Y, Tatsumi Y, Miyake M, Anai S, Kuwada M, Onishi S, Chihara Y, Tanaka N, Hirao Y, Fujimoto K (2016) Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. Photodiagn Photodyn Ther 13:225–232. https://doi.org/10.1016/j.pdpdt.2015.07.174 Google Scholar
- 44.Mowatt G, N’Dow J, Vale L, Nabi G, Boachie C, Cook JA, Fraser C, Griffiths TR (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care 27(1):3–10. https://doi.org/10.1017/s0266462310001364 Google Scholar
- 45.Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R (2010) Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 57(4):595–606. https://doi.org/10.1016/j.eururo.2009.11.041 Google Scholar
- 46.Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Fradet Y, Karl A, Burgues JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D (2013) Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64(5):846–854. https://doi.org/10.1016/j.eururo.2013.03.059 Google Scholar
- 47.Murata S, Iseki M, Kinjo M, Matsuzaki O, Moriuchi A, Ohtani H, Sakurai T, Satake T, Tsuzuki T (2010) Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Am J Clin Pathol 134(6):862–872. https://doi.org/10.1309/ajcpacnudwen9gn4 Google Scholar
- 48.Lee JY, Cho KS, Kang DH, Jung HD, Kwon JK, Oh CK, Ham WS, Choi YD (2015) A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC cancer 15:566. https://doi.org/10.1186/s12885-015-1571-8 Google Scholar
- 49.Gakis G, Fahmy O (2016) Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. Bladder Cancer (Amst Neth) 2(3):293–300. https://doi.org/10.3233/blc-160060 Google Scholar
- 50.Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D (2014) Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol 66(5):863–871. https://doi.org/10.1016/j.eururo.2014.06.037 Google Scholar
- 51.Tatsugami K, Kuroiwa K, Kamoto T, Nishiyama H, Watanabe J, Ishikawa S, Shinohara N, Sazawa A, Fukushima S, Naito S (2010) Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol 24(11):1807–1811. https://doi.org/10.1089/end.2010.0055 Google Scholar
- 57.Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, de la Rosette J (2016) The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol 70(3):506–515. https://doi.org/10.1016/j.eururo.2016.03.053 Google Scholar
- 58.Anderson C, Weber R, Patel D, Lowrance W, Mellis A, Cookson M, Lang M, Barocas D, Chang S, Newberger E, Montgomery JS, Weizer AZ, Lee CT, Kava BR, Jackson M, Meraney A, Sjoberg D, Bochner B, Dalbagni G, Donat M, Herr H (2016) A 10-item checklist improves reporting of critical procedural elements during transurethral resection of bladder tumor. J Urol 196(4):1014–1020. https://doi.org/10.1016/j.juro.2016.03.151 Google Scholar
- 60.Datta SN, Allen GM, Evans R, Vaughton KC, Lucas MG (2002) Urinary tract ultrasonography in the evaluation of haematuria—a report of over 1000 cases. Ann R Coll Surg Engl 84(3):203–205Google Scholar
- 61.Huguet J (2012) Transitional cell carcinoma of the upper urinary tract after cystectomy. Arch Esp Urol 65(2):227–236Google Scholar
- 64.Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, Suzuki K, Oshima H, Hara M, Shibamoto Y (2009) Urinary bladder cancer: diffusion-weighted MR imaging—accuracy for diagnosing T stage and estimating histologic grade. Radiology 251(1):112–121. https://doi.org/10.1148/radiol.2511080873 Google Scholar
- 66.Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K (2012) Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 83(1):e21–e27. https://doi.org/10.1016/j.ijrobp.2011.11.065 Google Scholar
- 67.Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF (2018) Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. https://doi.org/10.1016/j.eururo.2018.04.029 Google Scholar
- 69.Birkhauser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A, Thoeny HC (2013) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 64(6):953–960. https://doi.org/10.1016/j.eururo.2013.07.032 Google Scholar
- 72.Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, Siegel C, Cao D, Gao F, Siegel BA (2009) Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin oncol 27(26):4314–4320. https://doi.org/10.1200/jco.2008.20.6722 Google Scholar